Viking Therapeutics, Inc

XNASHealth care

Last traded price · USD

$27.91

+6.98%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:25 IST · A quote does not mean the product is available to trade on your account.

Day's open: $26.91
Previous close: $26.09
Volume: 4.4M
Day's high: $28.00
Day's low: $26.09

In brief

Viking Therapeutics, Inc is a health care company listed on Nasdaq, valued at about $3.56B.
Its shares closed at $27.97 on 4 Nov 2026, down 19.2% over the past year.
From India you can buy VKTX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Viking Therapeutics, Inc (VKTX) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole VKTX share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade VKTX options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −1.4% (SPY −1.6%, XLV +13.5%). 3 months: −16.5% (SPY −0.4%, XLV +15.5%). 1 year: −19.2% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: VKTX, SPY and XLV · as of 4 Nov 2026
Short interest at 20.0% of shares outstanding
25.5M shares were sold short at the 15 Oct 2026 settlement, 20.0% of the 127.5M shares outstanding; covering them would take 4.4 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $27.97 was 7.1% below its 50-day average ($30.10) and 13.4% below its 200-day average ($32.31). It has closed below the 200-day for 28 sessions, since 28 Sep 2026. The 50-day average crossed below the 200-day on 7 Oct 2026, 20 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
21% of the way up its 52-week range
Closed at $27.97 on 4 Nov 2026: 35.2% below the 52-week high of $43.15 (12 Nov 2025) and 17.4% above the low of $23.82 (27 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−1.4%

6 months−13.4%

1 year−19.2%

5 years+316.2%

Newswire

About

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Website

Notable moves

February 27, 2024
+121.02%
March 28, 2023
+69.30%
December 19, 2022
+73.88%

Viking Therapeutics, Inc

XNASHealth care

Last traded price · USD

$27.91

+6.98%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:25 IST · A quote does not mean the product is available to trade on your account.

Day's open: $26.91
Previous close: $26.09
Volume: 4.4M
Day's high: $28.00
Day's low: $26.09

In brief

Viking Therapeutics, Inc is a health care company listed on Nasdaq, valued at about $3.56B.
Its shares closed at $27.97 on 4 Nov 2026, down 19.2% over the past year.
From India you can buy VKTX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Viking Therapeutics, Inc (VKTX) shares from India?

Do I need the price of a whole VKTX share to invest?

How much can I invest in US stocks in a year?

Can I trade VKTX options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −1.4% (SPY −1.6%, XLV +13.5%). 3 months: −16.5% (SPY −0.4%, XLV +15.5%). 1 year: −19.2% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: VKTX, SPY and XLV · as of 4 Nov 2026
Short interest at 20.0% of shares outstanding
25.5M shares were sold short at the 15 Oct 2026 settlement, 20.0% of the 127.5M shares outstanding; covering them would take 4.4 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $27.97 was 7.1% below its 50-day average ($30.10) and 13.4% below its 200-day average ($32.31). It has closed below the 200-day for 28 sessions, since 28 Sep 2026. The 50-day average crossed below the 200-day on 7 Oct 2026, 20 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
21% of the way up its 52-week range
Closed at $27.97 on 4 Nov 2026: 35.2% below the 52-week high of $43.15 (12 Nov 2025) and 17.4% above the low of $23.82 (27 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−1.4%

6 months−13.4%

1 year−19.2%

5 years+316.2%

Newswire

About

Website

Notable moves

February 27, 2024
+121.02%
March 28, 2023
+69.30%
December 19, 2022
+73.88%

Viking Therapeutics, Inc

Viking Therapeutics, Inc in brief

Behind SPY and its sector fund XLV over 1 year

Short interest at 20.0% of shares outstanding

Below its 50- and 200-day averages

21% of the way up its 52-week range

Viking Therapeutics, Inc

Viking Therapeutics, Inc in brief

Behind SPY and its sector fund XLV over 1 year

Short interest at 20.0% of shares outstanding

Below its 50- and 200-day averages

21% of the way up its 52-week range